New Economics of the Biopharmaceutical Industries and Job Opportunities

Background Biopharmaceutical is either protein or nucleic acid based drug that is approved for therapeutic, diagnostic, or disease prevention applications. Methods This study was conducted by a careful bibliography and search through original pharmaceutical company websites such as Web of Sciences, Springer, Scopus, Pubmed, and Google scholar. Results The annual pharmaceutical company reporting season started a few months ago and brought exciting full-year events. The global market value was estimated US$780 billion in 2016, representing an accelerating trend with more than 4.9% growth for the industry. Johnson & Johnson was the first ranked company both globally and in the US with a market around $72 billion in 2016. Despite the growing challenges posed to the pharmaceutical companies, they are estimated to grow at an average rate of 6.3% per year, reaching $1.3 trillion by 2022. In 2016, biopharmaceutical products represented sales of $197 billion appropriated 24% of the global market. Antibodies alone had sales of $82 billion, near to half of the biopharmaceutical market. Conclusion Results from the health care world represent that the biopharmaceutical industries are spectacularly occupying the pharmaceutical market and they are expected to continue to grow up to 30% of global drug market in 2022. Oncology agents are recognized as the largest market value all around the world with a predicted annual growth of 12.5%, reaching approximately $190 billion in 2022. Therefore, it is not surprising to recognize Roche as the top ranking biopharmaceutical pipeline with innovative oncology projects in the industry. Roche is expected to be the best biopharmaceutical selling company, competing Novartis for the first spot in 2022. Keywords: Pharmaceutical Biotechnology , Biologic agents , Economics , Protei